Matica Biotechnology, a contract development and manufacturing organization (CDMO) specializing in clinical and commercial production of cell and gene therapies, has broken ground on its new 25,000 ft2 facility which will house its GMP virus production suites, development laboratories and company offices. The new building will be located at Providence Park in College Station, Texas. [Read more…]
Stem Cell News
BioInformant's coverage of stem cell news includes iPS cells, mesenchymal stem cells, hematopoietic stem cells, neural stem cells and more.
As the first and only market research firm to specialize in stem cell news, BioInformant research has been cited by the Wall Street Journal, Xconomy, AABB, and Vogue Magazine.
Serving Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in stem cell industry news.
AGC Biologics Announces the Expansion of Their Cell and Gene Therapy Facility in Milan, Italy
SEATTLE, March 2, 2021 — AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced plans for the expansion of their Cell and Gene Therapy Center of Excellence in Milan, to increase capacities and implement viral vector suspension capabilities. [Read more…]
Organicell and The Centers for Disease Control and Prevention Enter Into Agreement To Conduct Research on Influenza Viruses of Pandemic Potential
March 23, 2021, Miami — Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, today announced that it has entered into a Material Cooperative Research and Development Agreement with the Centers for Disease Control and Prevention (“CDC”) to determine the anti-inflammatory and anti-infective effectiveness of Zofin™ in experimental models of influenza infection. [Read more…]
denovoMATRIX Launches New Enabling Technology for High-Quality Induced Pluripotent Stem Cell Culture
DRESDEN, Germany, Mar. 22, 2021 (BioInformant) — denovoMATRIX GmbH, a developer of technologies which enable high quality stem cell expansion, announced the launch of a new range of products for the expansion, banking and maintenance of induced pluripotent stem cells (iPSC). The product line, termed myMATRIX iPSC, are chemically defined, ready-to-use consumables, designed to simplify and accelerate iPSC culture. [Read more…]
USPTO Issues New Patents for Cell Source’s Veto Cell Technology
Patents Validate Veto Cells as a Critical Enabler for Cell Therapies Such as CAR-T, TCR, and NK as well as a Powerful, Stand-alone Immunotherapy in the Treatment of Cancer, Viral and Bacterial Infections
March 19, 2021 – New York, NY – Cell Source, Inc. (OTC: CLCS) (“Cell Source” or the Company”), the world leader in Veto Cell based innovative immunotherapy technologies that safely facilitate mismatched donor stem cell transplants, e.g. bone marrow transplants (BMT) and organ transplants. In addition, Veto Cells can durably treat malignant and non-malignant blood diseases through active immune response management. Today, Cell Source announced that it has received USPTO issuance notices for two patents covering its Veto Cell technology. [Read more…]
